Skip to content

GoodRx Holdings, Inc. GDRX Capitalized software licenses

Capitalized software licenses at other companies

Omnicell logo
OmnicellOMCL

Other financials

Income statement

See full
Revenue$194.0M-4.4%
Gross profit$173.9M-8.3%
Operating income$14.0M-40.1%
Net income$1.2M-89.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$235.7M-21.7%
Total debt$541.4M0.0%
Total equity$622.0M-4.9%
Total assets$2.0B+56.0%

Cash flow

See full
Operating cash flow$11.8M+25.8%
CapEx$1.1M+700%
Free cash flow$10.7M+15.4%

Valuation

See full
Market cap$911.04M-44.5%
Enterprise value$1.22B-35.4%
P/E44.3×-13.4×
P/S1.2×-0.9×

Profitability

See full
Gross margin91.8%-2.0pp
Operating margin9.9%-0.3pp
Net margin2.6%-1.0pp
FCF margin21%+2.3pp

Returns & leverage

See full
Return on equity3.2%-1.2pp
Debt / equity0.9×0.0×
Current ratio1.5×-3.8×

Where this comes from

Reported directly by GoodRx Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CapitalizedComputerSoftwareNet.

The official record: GoodRx Holdings, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about GoodRx Holdings, Inc.'s capitalized software licenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GoodRx Holdings, Inc.'s capitalized software licenses?
GoodRx Holdings, Inc. (GDRX) reported capitalized software licenses of $140.19M in Q1 2026.
How has GoodRx Holdings, Inc.'s capitalized software licenses changed year-over-year?
GoodRx Holdings, Inc.'s capitalized software licenses increased by 7.4% year-over-year, from $130.58M to $140.19M.
What is the long-term trend for GoodRx Holdings, Inc.'s capitalized software licenses?
Over 5 years (2020 to 2025), GoodRx Holdings, Inc.'s capitalized software licenses has grown at a 47.7% compound annual growth rate (CAGR), from $19.8M to $139.26M.